RxDoctor Payments Data

Anne le

Optometrist · Houston, TXNPI 1568580637

Payments from drug & device makers

$2,309in general payments, 2019–2025

Across 48 payments — averaging $48.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Optos, Inc.$355
  • Bausch & Lomb Americas Inc.$319
  • Visioneering Technologies, Inc.$309
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$295
  • Novartis$210
  • Alcon$196
  • plus $625 from 7 others

What the payments were for

  • Food & beverage$2,05289%
  • Entertainment$25711%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,309 in reported general payments places this provider in the 75th percentile of 4,315 optometrist providers in Texas.

See all optometrist providers in Texas

Medicare billing

Part B allowed, 2024
$7,770
Medicare patients
39
Services billed
94

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine92$113,929
XiidraLifitegrast28$40,691
LumiganBimatoprost41$20,055
VyzultaLatanoprostene Bunod32$11,531
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol30$1,012
Prednisolone Acetate44$730
MoxifloxacinMoxifloxacin Hcl15$727
Latanoprost169$656
Azelastine Hcl66$388
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha47$367
Ofloxacin31$288
Ciprofloxacin Hcl11$103

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$67$133,984133 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$319$52,22260 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,315 optometrist providers in Texas.

Other optometrist in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →